- IV TPOXX is an Important Option for Those Unable to Swallow – - Option to Fund Post-Marketing Field Study for IV TPOXX also Exercised – NEW YORK , Aug. 09, 2022 (GLOBE NEWSWIRE) -- SIGA Technologies , Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company, today announced the

- Approximately $9 Million of Product Sales in the Second Quarter, including First Oral TPOXX® Sale to the U.S. Department of Defense and Approximately $5 Million of International Sales – - Received Approximately $60 Million of International Orders for Oral TPOXX® Year to Date, from Ten

NEW YORK , July 28, 2022 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company, today announced that management will host a webcast and conference call to provide a business update at 4:30 P.M. ET on Thursday, August 4 th , 2022.

SIGA to Supply TPOXX® to Support KaliVir’s Oncolytic Vaccinia Clinical Immunotherapy Program NEW YORK , July 15, 2022 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on the health security market, today announced a collaboration

- Approximately $26 Million of Orders Received from Canada under Existing Procurement Contracts – - Approximately $2 Million of Orders Received from Two New Jurisdictions - NEW YORK , July 12, 2022 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical

Treatment Approved for Smallpox, Monkeypox, Cowpox, and Vaccinia Complications NEW YORK , July 08, 2022 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on the health security market, today announced that the United Kingdom has

Orders Received from Two New Jurisdictions, and a Country in the Asia Pacific Region under an Existing Contract NEW YORK , June 23, 2022 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on the health security market, today

SIGA to Appear alongside Emergent Biosolutions and Tonix Pharmaceuticals NEW YORK , June 22, 2022 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on the health security market, today announced that its Chief Executive Officer,

- FDA approval provides an important option for those unable to take oral formulation of TPOXX - NEW YORK , May 19, 2022 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on the health security market, today announced that the U.S.

NEW YORK , May 12, 2022 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on the health security market, today announced that the U.S. Department of Defense ( DoD ) awarded a contract to SIGA for the procurement of up to